Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands

BACKGROUND: Infection with HPV 16 and 18, the major causative agents of cervical cancer, can be prevented through vaccination with a bivalent or quadrivalent vaccine. Both vaccines provide cross-protection against HPV-types not included in the vaccines. In particular, the bivalent vaccine provides a...

Descripción completa

Detalles Bibliográficos
Autores principales: Westra, Tjalke A, Stirbu-Wagner, Irina, Dorsman, Sara, Tutuhatunewa, Eric D, de Vrij, Edwin L, Nijman, Hans W, Daemen, Toos, Wilschut, Jan C, Postma, Maarten J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575363/
https://www.ncbi.nlm.nih.gov/pubmed/23390964
http://dx.doi.org/10.1186/1471-2334-13-75

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575363/
https://www.ncbi.nlm.nih.gov/pubmed/23390964
http://dx.doi.org/10.1186/1471-2334-13-75

Ejemplares similares